268 related articles for article (PubMed ID: 15606328)
21. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates: expanded roles in the treatment of patients with cancer.
Viale PH; Sanchez Yamamoto D
Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272
[TBL] [Abstract][Full Text] [Related]
23. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
24. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
Pecherstorfer M; Diel IJ
Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
[TBL] [Abstract][Full Text] [Related]
25. Ibandronate: pharmacology and preclinical studies.
Russell RG
Bone; 2006 Apr; 38(4 Suppl 1):S7-12. PubMed ID: 16531132
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
Bell R
Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
[TBL] [Abstract][Full Text] [Related]
27. The potential role of bisphosphonates in prostate cancer.
Oades GM; Coxon J; Colston KW
Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
[TBL] [Abstract][Full Text] [Related]
28. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
29. Utility of bisphosphonates in treating bone metastases.
Merlini G; Turesson I
Med Oncol; 1996 Dec; 13(4):215-21. PubMed ID: 9152972
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
31. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates: mechanism of action and role in clinical practice.
Drake MT; Clarke BL; Khosla S
Mayo Clin Proc; 2008 Sep; 83(9):1032-45. PubMed ID: 18775204
[TBL] [Abstract][Full Text] [Related]
34. Ibandronate in metastatic bone disease: a review of preclinical data.
Bauss F; Body JJ
Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
36. Ibandronate in oncology.
Burckhardt P
Cancer; 1997 Oct; 80(8 Suppl):1696-8. PubMed ID: 9362439
[No Abstract] [Full Text] [Related]
37. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
[TBL] [Abstract][Full Text] [Related]
38. Use of bisphosphonates in patients with metastatic bone disease.
Berenson JR; Lipton A
Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
[TBL] [Abstract][Full Text] [Related]
39. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients.
Body JJ; Coleman R; Clezardin P; Ripamonti C; Rizzoli R; Aapro M;
Eur J Cancer; 2007 Mar; 43(5):852-8. PubMed ID: 17258449
[TBL] [Abstract][Full Text] [Related]
40. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
